Biography
Ishwar Gilada: A medical doctor, specialized in Skin & STDs with special training in HIV management, Managing Director and Consultant in HIV/AIDS at Unison Medicare& Research Centre-India’s first private sector comprehensive HIV Care clinic; President of AIDS Society of India (a professional organization of physicians in HIV care); Secretary General of Peoples Health Org. (India). He was Secretary General of ASI from 2005-2011 and the Jt. Sec. of National AIDS Committee, Govt of India (1995-97). He was the first to raise alarm against AIDS in 1985, is known for bringing India on AIDS control map, had started India’s first AIDS Clinic-1986 and has expertise in HIV care in resource-poor settings. He had trained several doctors, nurses and social workers; he was Editor-Publisher of AIDS ASIA from 1993 to 2008. He initiated, managed, supervised, evaluated over 40 HIV/AIDS projects in India, addressed over 3700 public meetings and training programs in India and abroad, has 235 scientific papers at conferences, written chapters in books on AIDS/STDs. He was consultant for American Foundation for AIDS Research (AmFAR), World Vision, USAID; has more than 65 awards to his credit including the "Outstanding Young Person of the World" –Glasgow in 1995 and Annemarie Madison Award-Germany in 1999 in Munich, Germany where he was termed as ‘the Indian Machinegun against AIDS’.
Research Interest
Specialized in Skin & STDs with special training in HIV management
Biography
Dr. Guirakhoo joined GeoVax as Senior Vice President R&D in October 2015. Dr. Guirakhoo was named one of the ‘50 Most Influential People in Vaccines’ in Vaccine Nation’s 2014 list. His previous assignment was Chief Technology Officer at Vaxess Technologies, a Cambridge, MA, based biotechnology company researching thermostabilization of vaccines and biologics using silk fibroin protein. Prior to this, he served as Chief Scientific Officer at Hookipa Biotech in Vienna, Austria, developing vaccines against Cytomegalovirus and cancers based on a novel replication deficient viral vector platform. Prior to that, Dr. Guirakhoo held the position of Executive Director of External R&D at Sanofi Pasteur from 2007-20012. Before joining Sanofi Pasteur in 2007, Dr. Guirakhoo was Head of Virology Research at Acambis for 15 years. During this time, he co-invented the ChimeriVax TM -technology platform in association with St. Louis University. This platform utilizes the YF 17D vaccine virus as a vector to develop chimeric live viruses. The ChimeriVaxTM vector platform was successfully used in the development of innovative vaccines such as: a) a single dose vaccine against Japanese encephalitis (IMOJEV™), marketed in Asian countries by Sanofi, b) a single dose veterinary vaccine for the prevention of West Nile encephalitis (PREVNILE™), marketed by Merck Animal Health, and c) DENGVAXIA®, the world’s first dengue vaccine approved in Mexico and Brazil in December 2015 and marketed by Sanofi. This tetravalent vaccine represents a historic milestone for half of the world population who lives at risk of dengue. Dr. Guirakhoo has over 30 years of experience in developing vaccines against infectious diseases. Dr. Guirakhoo holds a BSc in Biology, a MSc in genetics, and a PhD in Virology from the Medical University of Vienna, Austria, and was awarded a National Research Council post-doctoral fellowship at the National Center for Disease Control and Prevention in Fort Collins, CO, from 1990-1992.
Research Interest
Biography
Catherine Mullié obtained a PhD in Microbiology and a PharmD at the University of Lille, France, in 1999. After a post-doc year at the Faculté de Medicine in Amiens (Laboratoire d’Immunologie, INSERM-EMI 0351), she was appointed as assistant professor at the Faculté de Pharmacie in Amiens in 2000 and joined the LG-2A (Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, UMR 7378 CNRS) in 2008. She has been a member of the French Society for Microbiology since 2000. Her research is focused on the development of new antimicrobial and antimalarial drugs, with a special interest in efflux-mediated antibiotic resistance in Pseudomonas aeruginosa and Acinetobacter baumannii. She currently heads the French part of a bilateral project funded by France and Algeria (Partenariat Hubert Curien Tassili) on this topic.
Research Interest
development of new antimicrobial and antimalarial drugs, with a special interest in efflux-mediated antibiotic resistance in Pseudomonas aeruginosa and Acinetobacter baumannii